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Summary
 
Galectin-1 (GAL-1), a member of a family of conserved 
 
b
 
-galactoside–binding proteins, has
been shown to induce in vitro apoptosis of activated T cells and immature thymocytes. We as-
sessed the therapeutic effects and mechanisms of action of delivery of GAL-1 in a collagen-
induced arthritis model. A single injection of syngeneic DBA/1 fibroblasts engineered to secrete
GAL-1 at the day of disease onset was able to abrogate clinical and histopathological manifesta-
tions of arthritis. This effect was reproduced by daily administration of recombinant GAL-1.
GAL-1 treatment resulted in reduction in anticollagen immunoglobulin (Ig)G levels. The cy-
tokine profile in draining lymph node cells and the anticollagen IgG isotypes in mice sera at the
end of the treatment clearly showed inhibition of the proinflammatory response and skewing
towards a type 2–polarized immune reaction. Lymph node cells from mice engaged in the gene
therapy protocol increased their susceptibility to antigen-induced apoptosis. Moreover, GAL-
1–expressing fibroblasts and recombinant GAL-1 revealed a specific dose-dependent inhibitory
effect in vitro in antigen-dependent interleukin 2 production to an A
 
q
 
-restricted, collagen type
2–specific T cell hybridoma clone. Thus, a correlation between the apoptotic properties of
GAL-1 in vitro and its immunomodulatory properties in vivo supports its therapeutic potential
in the treatment of T helper cell type 1–mediated autoimmune disorders.
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G
 
alectin (GAL)-1
 
1
 
 is a member of a growing family of
animal 
 
b
 
-galactoside–binding proteins, which are
highly conserved throughout animal evolution (1–3) and
share significant sequence similarities in the carbohydrate
recognition domain (1, 4). The precise functions of indi-
vidual members of this family have been difficult to assess
in vivo by virtue of their widespread expression and over-
lapping specificities (3–5). Nevertheless, GAL-1 has been
proposed to play key roles in a wide variety of biological
events involving carbohydrate recognition, such as cell ad-
hesion (6), cell growth regulation (7–9), metastasis (10),
and immunomodulation (11, 12).
This homodimeric protein, composed by subunits of
 
z
 
134 amino acids (1), recently has been shown to induce
in vitro apoptosis of activated mature T cells (13, 14) and
particular subsets of non- or negatively selected CD4
 
lo
 
CD8
 
lo
 
immature thymocytes (15). The apoptotic effect of GAL-1
depended upon the activation state of T cells and was me-
diated by engagement of CD43 or CD45, particularly the
polylactosamine-enriched CD45RO splicing product (13,
15). Expression of GAL-1 has been specially identified in
lymphoid organs such as thymus (16) and lymph nodes
(17), in activated macrophages (14, 18) and T cells (8), and
in immune privileged sites such as placenta (3, 19) and cor-
nea (20). All these observations suggest that GAL-1 could
play an important role in generating and maintaining cen-
tral and peripheral immune tolerance.
Rheumatoid arthritis (RA) is a common chronic au-
toimmune disease for which there is no effective therapy
capable of preventing long-term progression and joint
damage (21, 22). To test in vivo the immunoregulatory
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 CIA, collagen-induced arthritis; CII, col-
lagen type II; GAL-1, galectin-1; mGAL-1, mouse GAL-1; PI, propid-
ium iodide; RA, rheumatoid arthritis; rGAL-1, human recombinant
GAL-1; TDG, thiodigalactoside. 
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properties of GAL-1, we used a collagen-induced arthritis
(CIA) model, which is a widely accepted experimental
model for human RA (23). Murine CIA is induced in ge-
netically susceptible DBA/1 mice and resembles RA in that
both cellular and humoral mechanisms are involved in the
pathogenic process (21). Blood-derived cells that migrate
into joints, in conjunction with activated synovial cells,
produce inflammatory and type 1 cytokines together with
degradative enzymes that progressively lead to the destruc-
tion of cartilage and bone (21, 23).
Effective treatment of arthritis will require the elimina-
tion of arthritogenic lymphocytes that initiate and perpetu-
ate joint inflammation, as well as the induction of tissue re-
pair. Hence, GAL-1–induced apoptosis could provide for
an ideal mechanism using an endogenous naturally occur-
ring protein to terminate the autoimmune T cell attack,
preventing the expansion of dominant autoaggressive clones,
and assuring a minimum of detrimental bystander damage
to the local parenchyma (24–26).
Our study deals with the concept of an in vivo role for
GAL-1 in T cell–dependent immunoregulation and pro-
vides experimental data, using gene and protein therapy
strategies, aimed at validating GAL-1’s therapeutic potential.
 
Materials and Methods
 
Subcloning of Murine GAL-1 into pCDNA3 Expression Vector.
 
Murine GAL-1 cDNA (length, 495 bp) was obtained from the
IMAGE Consortium (HGMP Resource Centre, MRC, Cam-
bridge, UK; clone 330090) and subcloned immediately down-
stream of the CMV promoter of a HindIII/BamHI-cut pCDNA3
expression vector (Invitrogen) by using a PCR strategy. Oligo-
nucleotide primers (5
 
9
 
) and (3
 
9
 
) were ordered from Oswell.
For cloning purposes, the sense deoxynucleotide primer 5
 
9
 
-
CAAGCTTCCATGGCCTGTGGTCTGGTCGCCAGCA and
the antisense primer 5
 
9
 
-GGGATCCTCACTCAAGGCCACG-
CACTT contained a HindIII and a BamHI restriction site, re-
spectively, and 21 nucleotides that annealed to the coding se-
quence of mouse GAL-1 cDNA. The reaction mixture consisted
of 100 ng/ml cDNA, 100 mM of each primer, 0.20 mM dNTPs,
1.5 mM MgCl
 
2
 
, 1
 
3
 
 PCR buffer (10
 
3
 
 buffer: 500 mM KCl, 100
mM Tris-HCl, pH 8.3, 0.01% wt/vol gelatin), and 25 U/ml Taq
DNA polymerase (Appligen Oncor) to a final volume of 100 
 
m
 
l.
The amplification procedure included a denaturation step at 94
 
8
 
C
for 4 min, followed by 35 cycles of 1 min strand separation at
94
 
8
 
C, 1 min annealing at 56
 
8
 
C, and 3 min extension at 72
 
8
 
C, fol-
lowed by an elongation step of 10 min at 72
 
8
 
C. The PCR reac-
tion product was further purified by agarose gel electrophoresis,
and then phenol-extracted, ethanol-precipitated, and finally its
ends were blunted with Klenow fragment of DNA polymerase.
After digestion, with HindIII and BamHI, the 495-bp product was
ligated into the HindIII/BamHI sites of the eukaryotic CMV
promoter-driven expression vector pCDNA3 by using T4 DNA
ligase. The ligated DNA was then used for the transformation of
competent 
 
Escherichia coli
 
 DH5
 
a
 
 cells. Ampicillin-resistant clones
were screened for the presence of the insert by HindIII/BamHI
restriction. A recombinant clone that contained the 495-bp insert
was named mGAL-1 and expanded to mass culture, and the plas-
mid DNA was purified by equilibrium centrifugation in CsCl-
ethidium bromide gradients. DNA restriction enzymes were pur-
chased from New England Biolabs or Boehringer Mannheim.
 
Antigen-dependent IL-2 Production Using a Collagen Type II–spe-
cific T Cell Hybridoma.
 
In vitro antigen presentation assays were
performed trying to mimic the in vivo therapeutic protocols: for
the gene therapy protocol, a collagen type II (CII)-specific and
A
 
q
 
-restricted T cell hybridoma clone (HCQ.6) was stimulated
with CII (50 
 
m
 
g/ml) and cultured in 96-well plates at a density of
5 
 
3
 
 10
 
5 
 
cells/ml in the presence of splenocytes from naive DBA/1
mice (5 
 
3
 
 10
 
6
 
 cells/ml) as APCs, in DMEM supplemented with
10% FCS, 2-ME, streptomycin, penicillin, and glutamine as pre-
viously described (27). To analyze the influence of GAL-1 on an-
tigen presentation, mGAL-1– or pCDNA3-transfected DBA/1
fibroblasts were added to some wells at increasing concentrations
of 0.25, 0.5, and 1 
 
3
 
 10
 
6
 
 cells/ml in a final volume of 200 
 
m
 
l.
For the protein therapy protocol HCQ.6 cells were cultured in
identical experimental conditions in the presence of splenocytes
from naive DBA/1 mice and the specific antigen. Recombinant
GAL-1 was added to some wells at concentrations ranging from
0.04 to 4 
 
m
 
g/ml at different time points of the assay. To test the
specificity of the effect in both experimental protocols, some
wells were supplemented with thiodigalactoside (TDG) at 100 mM
or the rabbit polyclonal anti–GAL-1 Ab (1:50 or 1:100 dilutions).
Supernatants were collected after overnight culture and as-
sessed for IL-2 production by a standard ELISA using an anti–
mouse IL-2 capture Ab (18161D; PharMingen), a biotinylated
anti–mouse IL-2 detecting Ab (18172D; PharMingen), and the
streptavidin-biotinylated horseradish peroxidase complex. Con-
trols included HCQ.6 cells cultured with APCs in the absence of
the specific antigen; HCQ.6 cells cultured with CII in the ab-
sence of APCs; and APCs incubated with CII in the absence of
HCQ.6 cells. Anti-CD3–stimulated HCQ.6 cells were used as
positive controls of IL-2 secretion.
 
DNA Transfections.
 
GAL-1 expression was firstly assessed by
transiently transfecting mGAL-1 into COS-7 cells. In brief, ex-
ponentially growing cells were harvested 24 h before transfection
and replated at a density of 10
 
6 
 
cells/plate in 90-mm tissue culture
plates in DMEM (Bio-Whittaker) containing 10% FCS (GIBCO
BRL). Cells were then transfected with 20 or 30 
 
m
 
g of vector
DNA by the Ca
 
2
 
1
 
-phosphate method as previously described (28).
Also, conditionally immortalized syngeneic DBA/1 fibroblasts
were permanently cotransfected by the same method with 20 or
40 
 
m
 
g of mGAL-1 or pCDNA3 DNA and 2.5 
 
m
 
g of pSV2-Hygro
for hygromycin B selection, previously linearized with PvuI.
Transfected DBA/1 cells were selected in DMEM medium con-
taining 10% FCS, and 200 
 
m
 
g/ml hygromycin B (Boehringer
Mannheim). Hygromycin-resistant clones, transfected with mGAL-1,
were pooled and assessed by Western blot for expression of
mGAL-1. Cells transfected with pCDNA3 alone were maintained
as a population and were used as controls.
 
Western Blot Analysis.
 
Serum-free supernatants were col-
lected from transiently and permanently transfected cells, centri-
fuged at 1,000 
 
g
 
 for 5 min to discard cell debris, and stored frozen
at 
 
2
 
70
 
8
 
C. Then, 5 ml of these supernatants were made to 0.5%
SDS final concentration and boiled for 5 min. Proteins were pre-
cipitated with 9 vol of methanol overnight at 
 
2
 
20
 
8
 
C. This solu-
tion was then centrifuged at 4
 
8
 
C at 21,000 
 
g
 
 for 30 min in a SS34
Sorvall rotor (Sorvall Instruments) and the precipitated proteins
were dissolved in 200 
 
m
 
l SDS-PAGE loading buffer with 2-ME.
Cells were also collected in PBS by scrapping with a rubber po-
liceman and centrifuged at 1,000 
 
g 
 
for 10 min. The cell pellet was
resuspended in 1 ml of ice-cold lysis buffer containing 50 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 10 mM EDTA,
and a protease inhibitor cocktail (1 mM PMSF, 1 mg/ml leupep-
tin, 1 mg/ml pepstatin A, 10 mM iodoacetamide, and 1 mM so- 
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dium vanadate) and left on ice for 30 min. The solution was cen-
trifuged at 4
 
8
 
C for 10 min at 10,000 
 
g
 
 and the resultant cell lysate
was mixed 1:1 with 2
 
3
 
 SDS-PAGE loading buffer.
Samples corresponding to supernatants and cell lysates were
boiled for 5 min, cooled on ice, and resolved on a 14% PAGE.
After electrophoresis, the separated proteins were electroblotted
onto nitrocellulose membranes (Schleicher and Schüll) and
probed with a 1:500 dilution of a rabbit polyclonal anti–human
GAL-1 antibody obtained as previously described (29). Blots
were incubated with a 1:2,000 dilution of a horseradish peroxi-
dase–conjugated donkey anti–rabbit F(ab)
 
2
 
 IgG (Amersham In-
ternational), developed by using the ECL system and finally ex-
posed to Amersham Hyperfilm for 1 min. Recombinant GAL-1
was used as a positive control of immunodetection and quantita-
tion. Rainbow protein molecular weight markers were from
Amersham International.
 
Production of Recombinant GAL-1.
 
Human recombinant GAL-1
was obtained as described by Hirabayashi et al. (29). In brief, the
expression plasmid pH14GAL was constructed from the plasmid
pUC540 (Kan
 
R
 
) and a cDNA for GAL-1 derived from a human
lung cDNA library. 
 
E. coli
 
 strains of SCS1 and Y1090 were then
transformed with pH14GAL and GAL-1 expression was assessed
by Western blot analysis. Finally, the recombinant protein was
purified by affinity chromatography on an asialofetuin-agarose
column. The hemagglutinating activity was measured as previ-
ously described (14, 29) and the NH
 
2
 
-terminal amino acid se-
quence was determined with an ABI 477A pulsed-liquid se-
quencer (Applied Biosystems, Inc.). Lipopolysaccharide content
of the purified sample was 60 ng/mg protein, determined with a
colorimetric endotoxin determination reagent (Pyrodick).
 
Induction of Arthritis.
 
Bovine CII was purified from hyaline
cartilage as previously described (30). Male DBA/1 mice (8–12
wk old) were immunized with 100 
 
m
 
g of CII emulsified in CFA
(Difco) by intradermal injection at the base of the tail. The day of
the disease onset in our study oscillated between days 20 and 23
after immunization with CII with a 95% incidence by day 24.
Mice were maintained according to approved Home Office pro-
tocols and following Institute guidelines. The number of mice
used in these studies was the minimum required to achieve statis-
tical significance.
 
Experimental Design.
 
Two therapeutic protocols were used at
onset of arthritis in our study. One was a gene therapy protocol
in which DBA/1 fibroblasts expressing mGAL-1 were intraperi-
toneally injected into DBA/1 arthritic mice (
 
n
 
 5 
 
10) at the day of
disease onset (4 
 
3
 
 10
 
6 
 
cells/mouse). Cells permanently trans-
fected with pCDNA3 expression vector alone were injected in
the control group (
 
n
 
 5 
 
10). This number of cells was chosen
from previous experience as being sufficient to obtain a therapeu-
tic benefit when expressing IFN-
 
b
 
 and a TNF antagonist. The
other was a protein therapy protocol, which used recombinant
human GAL-1 (100 
 
m
 
g diluted in 100 
 
m
 
l PBS) administered daily
to DBA/1 mice (
 
n
 
 5 
 
10) by intraperitoneal injections over an
11-d period starting on the day of disease onset. Mice receiving
daily intraperitoneal injections of 100 
 
m
 
l PBS (
 
n
 
 5 
 
8) were used
as controls for this protocol. Due to inter-individual differences
between immunized mice, recombinant GAL-1 protein treat-
ment began on the corresponding day of arthritis onset of each
individual animal. For mice receiving gene therapy it was techni-
cally difficult to proceed on this manner so they all were injected
with cells on day 21.
 
Clinical Monitoring of Arthritis.
 
Starting on day 15 after immu-
nization, mice were inspected daily for onset of the disease and
macroscopic signs of arthritis according to two clinical parame-
ters: paw swelling and clinical score. Paw swelling was assessed by
measuring the thickness of the affected hind paw with calipers.
The clinical severity of arthritis was monitored and scored on a
daily basis using a scoring system as follows: 0,
 
 
 
normal; 1,
 
 
 
slight
swelling and/or erythema; 2,
 
 
 
pronounced edematous swelling; 3,
ankylosis. Each limb was graded, resulting in a maximal clinical
score of 12 per animal and expressed as the mean score on a given
day. Severity and limb recruitment was also assessed by counting
the number of affected paws. Arthritis was monitored over a 12-d
treatment period by a blinded observer, after which the mice
were killed. Inguinal lymph nodes and spleens were removed and
disaggregated, and cells were cultured in in vitro assays.
 
Histopathologic Assessment.
 
Arthritic hindpaws (one or two
per mouse) were removed post mortem on day 12 of arthritis,
fixed in 10% (wt/vol) phosphate-buffered formalin, and then de-
calcified in 5.5% EDTA in buffered formalin. Decalcified paws
were embedded in paraffin, sectioned, and stained with hematox-
ylin and eosin. Microscopic evaluation of arthritic paws was per-
formed in a blinded fashion. Arthritic changes in the ankle, distal
interphalangeal, proximal interphalangeal, and metacarpopha-
langeal joints were classified as normal, moderate, or severe based
on the following criteria: normal,
 
 
 
control nonarthritic joint;
moderate,
 
 
 
pannus formation, cartilage loss, synovitis, and erosions
present but intact joint architecture; severe,
 
 
 
marked synovitis,
with extensive erosions and disrupted joint architecture.
 
Anti-collagen Ab ELISA.
 
At day 12 after onset, serum levels
of anti-CII total IgG and the IgG1 and IgG2a isotypes were mea-
sured by modification of an ELISA as described previously (30).
In brief, microtiter plates (Nunc) were coated with 2 
 
m
 
g/ml na-
tive bovine CII, blocked, and incubated with serially diluted test
sera. Bound IgG was detected by incubation with alkaline phos-
phatase–conjugated goat anti–mouse IgG (Jackson ImmunoRe-
search Labs.) or sheep anti–mouse IgG1 or IgG2a (The Binding
Site), followed by substrate (dinitrophenyl phosphate). Plates
were washed three times between steps with 0.01% Tween 20/
PBS (vol/vol). Optical densities were measured at 405 nm in a
Wallac 1420
 
 
 
spectrophotometer. To obtain anti-CII antibody
concentrations, serum samples were titered in parallel to a stan-
dard of affinity-purified anti-CII IgG (30).
 
Cell Culture for Cytokine Determination.
 
As mice were killed,
spleens and inguinal lymph nodes were excised, teased apart to
make a single cell suspension, washed, and cultured in 96-well
plates at a density of 5 
 
3
 
 10
 
6
 
 cells/ml (200 
 
m
 
l/well) in DMEM
containing 10% heat-inactivated FCS, 2 mM glutamine, 100 U/ml
penicillin, 100 
 
m
 
g/ml streptomycin, and 2 
 
3
 
 10
 
-5
 
 M 2-ME. Cells
were cultured in medium alone, or in the presence of 5 
 
m
 
g/ml
Con A (Sigma Chemical Co.) or bovine CII (100 
 
m
 
g/ml) in
Tris-buffered saline. Supernatants were collected after 72 h,
which was found to be the optimal incubation time for cytokine
determination, and stored at 
 
2
 
20
 
8
 
C until analyzed. Levels of
IFN-
 
g
 
 and IL-5 were detected by a capture ELISA as previously
described (31). In brief, 96-well flat-bottomed plates (Corning)
were coated with the appropriate primary anticytokine capture
Ab (5 
 
m
 
g/ml) in PBS, incubated overnight at 4
 
8
 
C, and blocked
with 2% BSA in PBS. Samples and standards were then incubated
overnight at 4
 
8
 
C, and, after washing, biotinylated anticytokine
detecting Ab was added at a concentration of 2 
 
m
 
g/ml for 2 h.
Streptavidin-biotinylated horseradish peroxidase complex (Amer-
sham International) was finally added for 1 h at a 1:1,000 dilution
and the color was developed with 3,3
 
9
 
, 5,5
 
9
 
-tetramethylbenzi-
dine (Kirkegaard and Perry Labs.). The reaction was finally
stopped by adding 100 
 
m
 
l 4.5 N H
 
2
 
SO
 
4 and the optical density
was read at 450 nm in a Wallac 1420 spectrophotometer. Each388 Galectin-1 Suppresses Collagen-induced Arthritis
sample was assayed in triplicate and the results were presented as
the mean 6 SEM of three independent experiments. The anti-
body pairs used were as follows, listed by capture/biotinylated
detection: IFN-g, R4-GA2/XMG1.2; and IL-5, TRFK5/
TRFK4. All antibodies were supplied by the American Type
Culture Collection, courtesy of Dr. Abrams, DNAX (Palo Alto,
CA). Standard curves were generated using mouse recombinant
IFN-g and IL-5 at concentrations ranging from 4.5 to 10,000 pg/ml.
Analysis of Hypodiploid DNA Content. After treatment was
accomplished, inguinal lymph nodes and spleens were removed
and lymph node cells and splenocytes were subsequently analyzed
for susceptibility to antigen-induced apoptosis by measuring the
nuclear DNA content by flow cytometry as described by Nico-
letti et al. (32). Lymph nodes or spleens from mice with compati-
ble disease evolution were pooled together and analyzed. In brief,
cells corresponding to mGAL-1– and pCDNA3-treated animals
were cultured in 24-well plates (Corning) in complete medium at
a density of 2 3 106 cells/well in the absence or in the presence
of CII (100 mg/ml). Cells were recovered after 24 h, washed
with ice-cold PBS, and processed for apoptotic cell detection. In
brief, cell pellets were gently resuspended in 1 ml hypotonic fluo-
rochrome solution: 50 mg/ml propidium iodide (PI; Sigma
Chemical Co.), diluted in 0.1% sodium citrate plus 0.1% Triton
X-100 in 12 3 75 polystyrene tubes and kept at 48C for 3 h in
the dark. The PI fluorescence emission of individual nuclei was
filtered through a 585/42 nm band pass filter and measured on a
logarithmic scale by a FACScan® cytometer (Becton Dickinson).
Cell debris was excluded from analysis by appropriately gating on
physical parameters. The number of apoptotic cells was assessed
by evaluating the percentage of hypodiploid nuclei in the ,2 N
DNA peak (M1), and distinguished from necrotic cells by analyz-
ing the light scatter profile. Positive controls of apoptosis in-
cluded cells cultured in the presence of recombinant GAL-1 (4
mg/ml).
DNA Fragmentation Assay. Lymph node and spleen cells of
mGAL-1–treated or control mice were also processed for DNA
fragmentation as previously described (14). In brief, cells cultured
for 24 h in the absence or presence of CII (100 mg/ml) were
harvested, washed with TNE buffer (10 mM Tris-HCl, pH 7.5,
100 mM NaCl, and 2 mM EDTA, pH 8), and lysed by the addi-
tion of 0.5% SDS. Cell lysates were incubated at 56ºC for 3 h in
the presence of 100 mg/ml proteinase K. DNA was further puri-
fied by successive phenol–chloroform extractions and mixed with
3 M sodium acetate, pH 5.2, and absolute ethanol. The mixture
was incubated overnight at 2208C and the purified DNA was
washed, resuspended in TE buffer (10 mM Tris-HCl and 1 mM
EDTA, pH 7.5) and treated with 5 ml of 1 mg/ml DNase free-
RNase A for 1 h. Samples were finally resuspended in loading
dye and resolved on a 1.8% agarose gel in Tris-Borate-EDTA
buffer, containing 0.5 mg/ml ethidium bromide.
Statistical Analysis. The Mann-Whitney U test was used to
compare nonparametric data for statistical significance using the
Minitab computer package. The x2 test was used for analysis of
histological data.
Results
Permanently Transfected Syngeneic DBA/1 Fibroblasts Ex-
press High Levels of mGAL-1. Syngeneic DBA/1 fibro-
blasts (44) engineered to express mGAL-1 were used in the
in vivo gene therapy protocol. The CMV promoter-driven
pCDNA3 expression vector containing the 495-bp mGAL-1
cDNA insert was used to establish stable transfectants by
long-term hygromycin B selection. As it is clearly shown in
Fig. 1, cells constitutively expressed this b-galactoside–
binding protein in their whole cell lysates (lane I) not only
in its predominant monomeric form of apparent molecular
weight of 14.5 kD but also in its dimeric form of 29 kD.
Moreover, these cells were able to secrete GAL-1 to the
culture medium, as shown in lane J. Similarly, transiently
transfected COS-7 cells expressed high levels of GAL-1
(lanes D and E, 20 and 30 mg of transfected DNA, respec-
tively), although it could not be immunodetected in con-
centrated COS-7 culture supernatants (lanes F and G).
Neither COS-7 cells nor DBA/1 fibroblasts showed any
immunoreactivity with the anti–GAL-1 Ab when trans-
fected with control pCDNA3 expression vector alone, ei-
ther in their whole cell lysates (lanes C and K, respectively)
or in their cell culture supernatants (lane H for COS-7
cells). Affinity purified recombinant GAL-1, which was
used in the in vivo protein therapy protocol, gave rise to a
single protein band of the predicted molecular weight,
which immunoreacted strongly with the anti–GAL-1 Ab
(lanes A and B). To semiquantitatively assess the concentra-
tion of mGAL-1 in the medium of DBA/1-transfected
Figure 1. Western blot analysis of COS-7 cells
and DBA/1 fibroblasts engineered to express mu-
rine GAL-1. Cell extracts and supernatants of tran-
siently transfected COS-7 cells (lanes C–H) and
permanently transfected DBA/1 fibroblasts (lanes I–K)
were resolved on a 14% polyacrylamide slab gel,
transferred to nitrocellulose, and probed with a
1:500 dilution of an anti–GAL-1 Ab. The immu-
noreactive profile of rGAL-1 is indicated in lanes A
and B (0.75 and 1 mg, respectively). Extracts from
COS-7 cells transfected with mGAL-1 (lanes D and
E; 20 and 30 mg of transfected DNA, respectively)
or control pCDNA3 (lane C) were analyzed for
GAL-1 detection in parallel with their supernatants
(lane F, pCDNA3; lanes G and H, GAL-1). GAL-1
was highly expressed in cell extracts (lane I) and su-
pernatants (lane J) of transfected syngeneic DBA/1
fibroblasts but not in control transfectants (lane K).
Molecular mass standards are shown on the left.389 Rabinovich et al.
cells, we used different concentrations of recombinant
GAL-1 and scanned a Western blot. Assuming similar
epitopes are recognized by the polyclonal antibodies in the
human and murine proteins, 106 DBA/1 cells produced
0.32 mg/ml per 24 h mGAL-1. This assessment may be an
underestimation of the real mGAL-1 concentration.
GAL-1 Suppresses Clinical Manifestations of CIA. The po-
tential of GAL-1 to ameliorate joint disease was explored
by two different therapeutical approaches: gene therapy
and protein therapy. A single cell injection (4 3 106 cells/
mouse) at the day of disease onset of syngeneic DBA/1 fi-
broblasts engineered to express mGAL-1 was able to abro-
gate clinical manifestations of established CIA. In broad
agreement, overall disease progression was markedly atten-
uated when GAL-1 protein (100 mg/mouse per day) was
administered daily from the day of the arthritis onset.
Severity of arthritis was monitored by paw swelling (Fig.
2, a and d), clinical score (Fig. 2, b and e), and by the num-
ber of affected paws (Fig. 2, c and f). Pooled data from sep-
arate experiments showed that on day 12 after disease on-
set, gene therapy using mGAL-1–transfected fibroblasts
significantly reduced hind paw swelling (Fig. 2 a; P  5
0.0002) and arthritis progression as determined by the clin-
ical score (Fig. 2 b; P 5 0.0002), compared with control
constructs of pCDNA3-transfected fibroblasts. Disease
amelioration was clearly manifested and reached statistical
significance (P 5 0.01) as early as 3 d after the start of the
treatment. As to the protein therapy protocol, daily admin-
istration of GAL-1 protein from the day of the disease on-
set, resulted in a significant reduction on day 12 after onset
in hind paw swelling (Fig. 2 d; P 5 0.0008) and clinical
score (Fig. 2 e P  5 0.0009) to similar inhibitory levels
raised by gene therapy, in comparison to saline-treated
controls. Marked amelioration of CIA by GAL-1 was
clearly reflected by a reduction in the number of arthritic
paws as indicated in Fig. 2 c (gene therapy protocol) and f
(protein therapy protocol).
In brief, arthritic mice experienced a clear and remark-
able decline in the development of the ongoing inflamma-
tory disease when treated with GAL-1 by both therapeutic
strategies. The specificity of this therapeutic effect was
highlighted by the rapid progression and disease evolution
in virtually all mice treated with control pCDNA3-trans-
fected fibroblasts (Fig. 2, a–c) or PBS (Fig. 2, d–f).
GAL-1 Inhibits Histopathological Manifestations of CIA.
Histopathological findings tightly paralleled clinical data of
individual mice (Fig. 3). 12 d after disease onset, micro-
scopic analysis of hematoxylin and eosin–stained hind paw
sections showed that most of joints of GAL-1–treated mice
of both therapeutic protocols (Fig. 3, A and B) were only
mildly affected (P , 0.05; x2) in comparison to control
groups (Fig. 3 C). Synovitis, mononuclear cell infiltration,
and cartilage erosion were dramatically diminished in joints
corresponding to GAL-1–treated mice, particularly those
engaged in the gene therapy protocol (Fig. 3 D). 75% of
these mice showed normal joints and 20% mild joint le-
sions, consisting of small erosions limited to the cartilage–
pannus junction. In contrast, 65% of control mice exhib-
ited severe arthritis (Fig. 3 D) accompanied by massive
leukocyte infiltration, cartilage destruction, bone erosion,
and loss of joint integrity. Overall, protein therapy ap-
peared to be less effective at protecting joint structure than
was gene therapy (data not shown).
GAL-1 Reduces Anti-CII IgG Levels and Induces a Bias from a
Type 1– to a Type 2–mediated Immune Response. To deter-
mine whether GAL-1 could affect humoral responses to
CII over the treatment period, an analysis of anti-CII IgG
levels was performed on sera of treated and control mice
subjected to both therapeutic protocols. As shown in Fig. 4
a, arthritic mice engaged in the gene therapy protocol with
Figure 2. Therapeutic effect of GAL-1 in murine CIA. Arthritis was
induced in male DBA/1 mice by intradermal injection of 100 mg native
bovine CII in CFA. Hind paw swelling (a and d) was monitored with
calipers from the day of disease onset onwards and expressed in mm
(mean  6  SEM). Clinical score (b and e), was assessed as described in Ma-
terials and Methods (mean 6 SEM). Number of arthritic paws was as-
sessed visually (c and f) (mean 6 SEM). A single intraperitoneal injection
at the day of disease onset of mGAL-1 expressing DBA/1 fibroblasts (4 3
106 cells/mouse; panels a, b, and c, u; n 5 10), or daily administration for
11 d of recombinant GAL-1 (100 mg) from the day of established arthritis
(d, e, and f, u; n 5 10), was able to significantly reduce paw swelling in
comparison to pCDNA3 control transfectants (a, b, and c, r; n 5 10) or
saline-treated mice (d, e, and f, r; n 5 8). SEM bars are not shown
where they are smaller than the symbol. Two sets of independent in vivo
experiments were carried out with very similar results. The results shown
are representative of one such experiment.390 Galectin-1 Suppresses Collagen-induced Arthritis
mGAL-1 experienced a biologically and statistically signifi-
cant reduction in total anti-CII IgG levels (P 5 0.0048) 12 d
after the start of the treatment, compared with control mice
treated with pCDNA3-transfected fibroblasts. This dra-
matic decline in anti-CII IgG levels was clearly manifested
in mice receiving a daily dose of recombinant GAL-1 (Fig. 4
d; P 5 0.0018) in comparison to saline-treated controls. It
should be emphasized that overall reduction in anti-CII
IgG levels by GAL-1 was strictly correlated in each indi-
vidual mouse with marked amelioration of joint disease.
It has been hypothesized that the balance of cytokines
produced by Th1/Th2 subsets of T helper cells plays an
important role in the development of the autoimmune re-
sponse (21) and that a type 2 cytokine pattern is involved in
the remission of CIA (31). This prompted us to investigate
whether GAL-1 treatment could modify the Th1/Th2 bal-
ance in the arthritogenic process. Thus, anti-CII IgG2a
(Th1) and IgG1 (Th2) subclasses were further determined
in sera of treated and control mice, after gene and protein
therapy with GAL-1. A definitive reduction in anti-CII
IgG2a isotype (Fig. 4 b; P 5 0.00147), accompanied by a
slight but significant increase in absolute levels of anti-CII
IgG1 (Fig. 4 c; P 5 0.0048) were observed at the end of
the treatment in sera of DBA/1 mice engaged in the gene
therapy protocol in comparison to control mice. In broad
agreement, treatment with recombinant GAL-1 resulted in
a pronounced shift from an IgG2a (Fig 4 e; P 5 0.0018) to
an IgG1 isotype profile (Fig. 4 f; P 5 0.0055) in compari-
son to saline-treated controls.
To elucidate whether class switching to IgG1 was corre-
lated with changes in the cytokine secretion pattern, in-
guinal lymph nodes and spleens were excised at the end of
the treatment from GAL-1–treated or untreated mice.
Cells were cultured in the presence of CII and supernatants
were analyzed after 72 h for IFN-g (Fig. 5 a) and IL-5 (Fig.
5 b) production. The main differences were found at the
level of draining lymph nodes of mice engaged in the gene
therapy protocol with GAL-1, where IL-5 raised to mean
high levels of 1,800 pg/ml (P , 0.005), in comparison to
the lower levels exhibited by arthritic mice, treated with
control vector alone (,250 pg/ml). Consistently, gene
Figure 3. Histopathological assessment of arthritic joints. Mice treated
with mGAL-1–transfected fibroblasts (4 3 106 cells/mouse) showed
mainly normal joints (A) and some moderately arthritic joints (B). Con-
trol mice treated with pCDNA3-transfected cells (4 3 106 cells/mouse)
showed moderate (B) and severe arthritis (C) accompanied by synovitis,
erosions, and loss of joint integrity. A–C, hematoxylin and eosin staining;
original magnification: 3100. Percentage of histological score per group
is shown in D.
Figure 4. Reduction of total anti-CII IgG levels in sera from GAL-
1–treated mice and changes in anti-CII IgG2a and IgG1 isotypes. Ar-
thritic mice engaged in the gene therapy (a, b, and c) or protein therapy (d,
e, and f) protocols were killed on day 12 after onset and terminally bled,
and sera were analyzed for total anti-CII IgG levels by standard ELISA
as described in Materials and Methods. Mice receiving mGAL-1–
expressing  fibroblasts or recombinant GAL-1 (white bars) had a signifi-
cant reduction in anti-CII Ab levels in comparison to control mice re-
ceiving pCDNA3 control fibroblasts or saline (black bars). A significant
increase in anti-CII IgG1 levels was seen in all the GAL-1–treated groups
as compared with their controls. Mean values of different groups (n 5 10)
are shown (mean 6 SEM).391 Rabinovich et al.
therapy with GAL-1 resulted in a severe decline in IFN-g
to background levels of ,50 pg/ml (P , 0.005), whereas
the control group secreted large amounts of this proinflam-
matory cytokine (.500 pg/ml). No significant differences
in cytokine secretion could be detected at the level of
spleens between experimental and control groups (data not
shown).
In brief, GAL-1 treatment promoted a clear shift of the
arthritogenic process, mainly at the level of draining lymph
node cells, skewing the balance towards a type 2–polarized
immune response and inducing a remission state in the
evolution of the ongoing inflammatory autoimmune disease.
Susceptibility to Antigen-induced Apoptosis Is Increased in
GAL-1–treated Mice. It is well known that T cells cycling
in response to antigenic stimuli are driven into apoptosis by
potent TCR restimulation (33). Since GAL-1 has been
shown to trigger apoptosis of activated T cells in vitro (13,
14), we investigated whether this protein was able to in-
crease the susceptibility of T cells in vivo to antigen-induced
apoptosis, thus providing a potential explanatory mecha-
nism for the suppression of the arthritogenic process.
Mice engaged in the gene therapy protocol were killed
at the end of the treatment, draining lymph nodes and
spleens were excised, and cells were cultured for 24 h in
the presence or absence of CII for apoptotic cell detection.
Lymph node cells from all GAL-1–treated mice experi-
enced higher susceptibility to antigen-induced apoptosis
(Fig. 6 B), as shown by FACS® analysis of hypodiploid
DNA content (38 6 3%) and the increased ladder pattern
of DNA cleavage into oligonucleosomal-sized fragments of
z180–200 bp (inset, lane 2). Moreover, microscopic ex-
amination of lymph node cells revealed the typical features
of apoptosis, including chromatin condensation and reduc-
tion of the cytoplasmic volume (data not shown). In con-
trast, pCDNA3-treated mice (Fig. 6 A) showed back-
ground levels of hypodiploid DNA content (9 6 2%) and
lower levels of fragmentation (inset, lane 1). In the absence
of CII, the levels of apoptosis were between 2 and 6% in
both experimental groups.
On the other hand, no significant differences could be
detected between splenocytes from experimental and con-
trol groups in their susceptibility to undergo apoptosis in
response to TCR restimulation (data not shown). The re-
sults presented herein suggest a correlation between the
molecular properties reported for GAL-1 in vitro (14, 18)
and its therapeutic potential in vivo.
GAL-1 Impairs T Cell Function during Antigen Presentation
to a CII-specific T Cell Hybridoma. The experimental con-
ditions used by gene and protein therapy in vivo were re-
produced in vitro to study the influence of GAL-1 on IL-2
production and apoptosis during antigen presentation. The
capacity of splenocytes from naive DBA/1 mice to present
CII to an Aq-restricted, CII-specific T cell hybridoma
clone (HCQ.6) was evaluated in the presence of mGAL-1–
transfected syngeneic fibroblasts. After 24-h cultures, cell
supernatants were collected and analyzed for IL-2 production.
The presence of mGAL-1–transfected fibroblasts de-
creased the level of IL-2 production in one order of magni-
tude, when added at concentrations of 5 3 105 to 1 3 106
cells/ml (Table I). No changes in IL-2 production could be
detected when fibroblasts were added at 2.5 3 105 cells/ml,
indicating a critical inhibitory concentration. As clearly
shown, TDG, a b-galactoside–specific sugar, was able to
partially prevent this effect when added at a concentration
of 100 mM, while the anti–GAL-1 Ab did not neutralize
GAL-1 activity at any of the dilutions tested (data not
shown).
For extrapolation to the protein therapy protocol, the
capacity of rGAL-1 to inhibit T cell function during CII-
specific activation of HCQ.6 cells was also studied. As de-
duced from Table II, a dose- and time-dependent inhibi-
tory effect on IL-2 production was observed when GAL-1
was added at concentrations ranging from 0.04 to 4 mg/ml
at different time points of the assay. Interestingly, 2 h of in-
cubation with rGAL-1 at 4 mg/ml were sufficient to totally
abrogate IL-2 secretion, whereas 4 h were required to
achieve maximal apoptotic effect as assessed by DNA frag-
mentation assay (data not shown). This indicates different
mechanisms leading to IL-2 inhibition and apoptosis. As
mentioned for transfected fibroblasts, rGAL-1 inhibitory
activity was partially counteracted by TDG but not by the
specific antigalectin Ab, confirming that the carbohydrate
recognition domain was clearly involved in this function
and that this polyclonal Ab had no neutralizing capacity.
The peak in IL-2 production was confirmed by incubating
HCQ.6 cells with anti-CD3 mAb, whereas background
levels of this cytokine were obtained when APCs or CII
were respectively omitted from the assay.
Figure 5. Cytokine profile in draining lymph node cells after gene
therapy with mGAL-1. Arthritic DBA/1 mice treated with mGAL-1
transfected cells (white bars) or control transfectants (black bars) were
killed on day 12 after onset. Inguinal lymph nodes from two mice with
compatible clinical scores were excised and pooled together. Cells (5 3
106 cells/ml) were cultured in triplicate in 96-well plates in the presence
of CII (100 mg/ml). After 72 h, supernatants were collected and analyzed
for IFN-g (a) and IL-5 (b) detection by a capture ELISA. Controls in-
cluded cells cultured in medium alone or with 5 mg/ml Con A (data not
shown). Mean values of different groups are indicated (mean 6 SEM) as a
combination of two independent experiments.392 Galectin-1 Suppresses Collagen-induced Arthritis
Taken together, these findings unequivocally suggest an
inhibitory effect of GAL-1 on antigen-specific T cell func-
tion. Finally, to address the possibility that this effect could
be related to galectin’s apoptotic properties, HCQ.6 cells
alone were incubated in the presence of GAL-1, revealing
a time-dependent increase on DNA fragmentation and
hypodiploid DNA content, when GAL-1 was added at its
highest concentration of 4 mg/ml, which has been previ-
ously shown to be the critical apoptotic threshold (14, 34)
(data not shown). This high concentration of GAL-1 is
probably necessary because it exists as a monomer at lower
concentrations. It has been shown that the dimeric form of
GAL-1 is required for its biological effect (13, 15), which
is probably needed for cross-linking of cell surface receptors.
Figure 6. Increased susceptibility of
lymph node cells to antigen-induced apop-
tosis after gene therapy with GAL-1. Ar-
thritic mice receiving mGAL-1–transfected
fibroblasts (B; n 5 10) or control pCDNA3
transfectants (A; n 5 10) were killed on day
12 after onset. Inguinal lymph nodes from
two mice with compatible clinical scores
were excised and pooled together. Cells
(5 3 106 cells/ml) were cultured in 24-well
plates in the presence of CII (100 mg/ml).
After 24 h, cells were collected and pro-
cessed for apoptotic cell detection. FACS®
analysis revealed increased hypodiploid
DNA content after PI staining in mGAL-1–
treated mice (B), in a representative one out
of five independent histograms with com-
patible results. In histograms: x axis, PI up-
take (FL2-H); y axis, relative cell number (counts). Lymph nodes cells from galectin-treated mice showed higher levels of DNA fragmentation (inset, lane
2) compared with controls (inset, lane 1). Positive controls of apoptosis (up to 85%) included cells cultured in the presence of 4 mg/ml recombinant
GAL-1 for 18 h (data not shown).
Table I. mGAL-1–expressing Cells Induce Dose-dependent Inhibition of IL-2 Production during Antigen Stimulation of an Aq-restricted,
CII-specific T Cell Hybridoma
HCQ.6 cells
(5 3 105/ml)
Spleen APC
(5 3 106/ml)
CII
(50 mg/ml) DBA/1 mGAL-1 DBA/1 PCDNA-3
TDG
(100 mM) IL-2
cells/ml cells/ml pg/ml
11 1 – 878.0 6 20.09
11 1 106 – 51.13 6 9.37*
11 1 5 3 105 – 51.64 6 7.25*
11 1 2.5 3 105 – 581.83 6 89.83
11 1 106 – 653.66 6 50.01
11 1 5 3 105 – 595.10 6 84.74
11 1 2.5 3 105 – 581.01 6 90.96
11 1 106 1 244.04 6 39.45
11 1 5 3 105 1 252.39 6 67.53
1 – 1 – 33.06 6 3.25
11 – – 35.38 6 1.37
HCQ.6 (5 3 105 cells/ml), an Aq-restricted, CII-specific T cell hybridoma, was stimulated with bovine CII (50 mg/ml) presented by splenocytes
from naive DBA/1 mice (5 3 106 cells/ml) in the presence of syngeneic fibroblasts transfected with mGAL-1 construct or control pCDNA3 expres-
sion vector. Specificity was assayed by adding TDG (100 mM) to the culture. Cells were cocultured for 24 h and IL-2 was measured in the superna-
tants by a capture ELISA. Anti-CD3–stimulated HCQ.6 cells reached maximal levels of IL-2 secretion (1,475 6 204 pg/ml). Anti–GAL-1 rabbit an-
tibody used at a dilution of 1:100 did not reverse the inhibition by GAL-1, indicating that it had no neutralizing activity (data not shown).
*P , 0.005; versus HCQ.6 cultured with APC and CII.393 Rabinovich et al.
Discussion
Attempts to dissect the functional roles for GAL-1 in
vivo have been unsuccessful in comparison to the over-
whelming information reached at the biochemical and mo-
lecular level. Targeted disruption of GAL-1 gene in knock-
out mice resulted in the absence of major phenotypic
abnormalities, suggesting that other proteins could poten-
tially compensate for the absence of GAL-1, as suggested
for null mutations in ostensibly important genes (5). Nev-
ertheless, their conservation throughout animal evolution
and their widespread distribution, strongly suggest that they
could be implicated in critical biological functions such as
cell adhesion (6), cell growth regulation (7–9) and immu-
nomodulation (11, 12).
In this study we provide definitive experimental data
supporting the concept of an in vivo therapeutic role for
GAL-1 in a murine experimental model of RA, by using
gene and protein therapy strategies. A single injection at
the day of the disease onset of genetically modified DBA/1
fibroblasts engineered to secrete GAL-1 was sufficient to
achieve a dramatic arrest in overall disease progression, as
judged by clinical, histopathological, and immunological
manifestations of arthritis. This effect was reproduced by
continuous daily administration of recombinant GAL-1.
Research over the past decade identified immunomodu-
latory properties for b-galactoside–binding proteins in two
experimental models of autoimmune myasthenia gravis
(11) and autoimmune encephalomyelitis (12). However,
only in the last few years has evidence been raised concern-
ing the molecular mechanism involved in these properties.
GAL-1 has been shown to induce in vitro apoptosis of acti-
vated T cells (13, 14, 34) through the recognition of selec-
tively glycosylated receptors such as CD43 and CD45, par-
ticularly the CD45RO splicing product (35). Furthermore,
GAL-1 has been implicated in T cell receptor–mediated
apoptosis, as a gear of the complex machinery involved in
the elimination of nonselected or negatively selected cells
during thymocyte maturation (15, 52).
Results presented here establish for the first time a corre-
lation between in vitro apoptotic properties of GAL-1 and
its therapeutic potential in vivo, providing an ideal nonin-
flammatory mechanism to terminate the autoimmune T
cell attack. Susceptibility to apoptosis was increased in
lymph node cells from mice engaged in the gene therapy
protocol. Hence, GAL-1–induced apoptosis might elimi-
nate the first wave of arthritogenic T cells, which are re-
sponsible for clinical disease and thus prevent the expansion
of dominant autoaggressive clones and concomitant epi-
tope spreading (26). The importance of dysregulated apop-
tosis in the etiology of autoimmune diseases has been high-
lighted by the occurrence of autoimmune disorders in
Table II. Concentration and Time-dependent Inhibition of IL-2 Production by rGAL-1 upon Antigen Cell Stimulation of an Aq-restricted, 
CII-specific T Cell Hybridoma
HCQ.6 cells
(5 3 105/ml)
Spleen APC
(5 3 106/ml)
CII
(50 mg/ml) rGAL-1
TDG
(100 mM) IL-2
mg/ml pg/ml
11 1 611.00 6 32.15
11 1 4 (18 h) – 25.90 6 3.2*
11 1 4 (4 h) – 29.95 6 2.21
11 1 4 (2 h) – 56.52 6 4.53
11 1 0.4 (18 h) – 48.77 6 6.25*
11 1 0.4 (4 h) – 97.13 6 9.37
11 1 0.4 (2 h) – 382.59 6 12.91
11 1 0.04 (18 h) – 362.10 6 21.89‡
11 1 0.04 (4 h) – 399.60 6 20.82
11 1 0.04 (2 h) – 400.02 6 12.93
11 1 4 (18 h) 1 119.22 6 7.93
11 1 4 (4 h) 1 203.57 6 9.64
12 1 – 33.57 6 1.96
11 – – 29.45 6 2.53
HCQ.6 (5 3 105 cells/ml), an Aq-restricted, CII-specific T cell hybridoma, was stimulated with bovine CII (50 mg/ml) presented by splenocytes
from naive DBA/1 mice (5 3 106 cells/ml) in the presence of rGAL-1 (0.04, 0.4, or 4 mg/ml), added for different time periods (2, 4, or 18 h) as in-
dicated. Specificity was assayed by adding TDG (100 mM) to the culture. The anti–GAL-1 Ab (1:100) had no neutralizing activity (data not shown).
Cells were cocultured for 24 h and IL-2 was measured in the supernatants by a capture ELISA. Anti-CD3–stimulated HCQ.6 cells reached maximal
levels of IL-2 secretion (1,147 6 165 pg/ml).
*P , 0.002; ‡P , 0.05 versus HCQ.6 cultured with APC and CII.394 Galectin-1 Suppresses Collagen-induced Arthritis
MRL-lpr/lpr or C3H-gld/gld mice strains that carry sponta-
neous mutations in Fas or Fas ligand genes (36), and in par-
ticular by the dominant Fas gene mutation associated to
Canale-Smith syndrome, a human autoimmune lympho-
proliferative disorder (37).
Two major pathogenic processes have been clearly identi-
fied in the development of RA, the first involving abnormal
synoviocyte proliferation, and the second dependent on T
cell and macrophage activation (38). Hence, attempts to in-
duce apoptosis either in rheumatoid synovium or activated
immune cells will be clearly beneficial for the treatment of
joint disease. In this context, Okamoto et al. (39) investi-
gated the apoptotic effects of Fas ligand–transfected cells on
proliferating human rheumatoid synovium engrafted in se-
vere combined immunodeficient mice. Moreover, Zhang et
al. (40) reported the amelioration of CIA after adenoviral-
mediated gene transfer of Fas ligand to arthritic joints.
GAL-1 treatment resulted in an overall reduction of
anti-CII Ab levels, skewing the balance towards a type
2–mediated immune response, a novel function for a b-galac-
toside–binding protein, which remains to be further inves-
tigated. Nevertheless, one might speculate that the ongoing
autoimmune response, mainly driven by Th1-proinflam-
matory cells, could be inhibited by apoptosis of memory
and activated T cells (13). Once the inflammatory action of
type 1 cytokines has been removed, it is feasible that a pre-
viously repressed Th2 response will become apparent. This
observation may provide a potential association between
GAL-1–induced apoptosis and immune deviation. Sup-
porting our finding, Varadhachary et al. (41) and Zhang et al.
(42) have recently reported that only Th1 effector cells
were susceptible to TCR- and Fas ligand–mediated apop-
tosis, leading to selective Th2 survival. Moreover, the re-
sults we obtained by GAL-1 treatment regarding a Th1/
Th2 switch are quantitatively stronger than those we previ-
ously reported expressing a soluble TNF receptor (43) or
IFN-b (44). The change in Ig isotypes, i.e., reduction in
IgG2a and increase in IgG1, reflects the change in T cell
help and has important therapeutic implications. IgG2a is a
complement fixing antibody, contributing to tissue damage
by triggering the production of anaphylatoxins that lead to
extravasation and infiltration of neutrophils which in turn
secrete pathogenic mediators of inflammation. This effect
on the humoral response is relevant also in multiple sclero-
sis and myasthenia gravis where antibodies and comple-
ment have been implicated, as in RA, in the pathology of
the disease.
It seems that a novel paradigm is providing a break-
through in galectin research. Overall opposite functions
from GAL-1 have been assigned to galectin-3, a 29-kD
member of this protein family with similar carbohydrate
specificity. GAL-1 has been shown to induce T cell apop-
tosis (13, 14), whereas galectin-3 has been conversely
shown to prevent cell death (45). Thus, galectin-1 and -3
may represent an additional family of proteins similar to the
Bcl-2 family, where different members exhibit sequence
similarity, yet have the opposite effects on cell survival (46).
In view of the results presented in this paper, the limits of
the paradigm could be further extended to the regulation
of the Th1/Th2 balance. Recent findings suggest that ga-
lectin-3 inhibited the transcription and release of IL-5 pro-
tein from antigen-specific T cell lines and human eosino-
phils (47). On the other hand, our results demonstrate the
ability of GAL-1 to skew the immune response in vivo to-
wards a Th2 profile, inducing a decrease in IFN-g and a
clear increase in IL-5 production.
Finally, we have also demonstrated that GAL-1–trans-
fected fibroblasts as well as recombinant GAL-1 induced a
specific and dose-dependent inhibitory effect in vitro using
a CII-specific T cell hybridoma clone. Increasing concen-
trations of GAL-1 augmented apoptosis and inhibited IL-2
secretion.These two effects appear to be regulated by dif-
ferent signaling pathways (52). It is important to note that
the dose-dependent effect was greatly enhanced during
antigen presentation, i.e., triggering through the TCR.
Without specific antigen, GAL-1 had to be added to the
cell culture at the high concentration of 4 mg/ml to get sig-
nificant apoptosis (data not shown). Our results strengthen
the hypothesis put forward by Perillo et al. (15) and Vespa
et al. (52) that thymocytes and T cells of the CD41CD81,
CD42CD82, CD41CD82, and CD42CD81 are more
sensitive to GAL-1–induced apoptosis after triggering of
their TCR with anti-CD3 Ab. Thus, it appears that GAL-1
induces a second signal that together with TCR signaling
sensitizes dividing T cells to apoptose (15, 52). The fact
that in our experiments lymph node cells and not spleen-
derived cells showed clear effects after GAL-1 treatment in-
dicates that alternative signaling mechanisms could function
in different organs that regulate GAL-1–induced functions.
Localization of GAL-1 in lymphoid organs such as thy-
mus (16) and lymph nodes (17) support the idea that GAL-1
may play a key role in the context of the immune system.
In this regard, using an mRNA differential display PCR,
GAL-1 gene was found to be induced in activated but not
resting T cells and then secreted to the extracellular milieu
to act as an autocrine negative growth factor (8). Conse-
quently, we recently purified a proapoptotic GAL-1–like
protein from peritoneal rat macrophages (14), and found
that its expression was differentially regulated according to
the activation state of the cells (18).
In our study, gene therapy using GAL-1–secreting fibro-
blasts reached similar therapeutic benefits to those found by
daily administration of GAL-1. However, gene therapy of-
fers unique advantages such as a single injection and thera-
peutic effects at lower concentrations and in a local envi-
ronment, overcoming the adverse effects of protein therapy
(22, 48, 49). Gene transfer strategies for RA (38) are cur-
rently designed for inhibiting proinflammatory cytokines
(43, 50, 51), matrix-degrading enzymes (38), and survival
of activated synovial cells (38, 39). Despite the advantages
of gene therapy, the majority of the work to date refers to
the constitutive expression of therapeutic genes. As with
GAL-1, long-term expression of biological agents can have
secondary effects such as altering the immune response to in-
fectious pathogens such as viruses (49). To prevent such an
outcome, transcriptionally regulated gene expression is395 Rabinovich et al.
necessary. The use of the tetracycline-inducible operon,
which is activated by tetracycline derivatives already used in
the clinic, is a possible solution to this problem (54).
To our knowledge, this study is the first approach aimed
at using the survival of activated arthritogenic T lympho-
cytes as a therapeutic target and that uses a naturally occur-
ring protein and not a synthetic compound such as bisin-
dolylmaleimide VIII (53).
In recent years it has been postulated that bone marrow
transplantation is the way to treat certain autoimmune dis-
eases such as RA and multiple sclerosis (55, 56). The hy-
pothesis behind this proposal is that the old “memory” of
autoimmune disease will be deleted by radiation therapy
while newly transplanted bone marrow will be tolerized to
the current autoantigens driving the immune response.
This resetting of the immune system may also be induced
by GAL-1 treatment. Further experiments will be required
to evaluate these interesting clinical applications.
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